Rosuvastatin is a novel statin that has been shown to produce large dose-dependent reductions in low-density lipoprotein cholesterol (LDL-C) in Western hypercholesterolemic patients. Rosuvastatin dose response was assessed in a randomized, doubleblind phase II trial in which 112 Japanese patients with fasting LDL-C > 160 and < 220 mg/dl and triglycerides < 300 mg/dl received placebo or rosuvastatin 1, 2. 
Introduction
Rosuvastatin is a novel statin developed by Shionogi and Company in Japan and subsequently licensed to AstraZeneca. The compound is characterized by unique binding to the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase active site, high inhibitory potency against the enzyme in vitro and in vivo, relative lipophilicity, selective uptake and activity in hepatic cells, and absence of significant metabolism by cytochrome P450 isoenzymes (1) (2) (3) (4) (5) (6) . In a dose-ranging study of hypercholesterolemic European patients, rosuvastatin 1 to 40 mg reduced low-density lipoprotein cholesterol (LDL-C) by 36-63% in a dose-dependent manner and pro-duced marked beneficial changes in other lipid variables (7) . Since then, rosuvastatin has been shown to reduce LDL-C significantly more than atorvastatin and other statins in a number of studies in Western patients (8) (9) (10) (11) . Responses to low doses (1 to 4 mg) of rosuvastatin in Japanese patients have been reported (12) .
Hypercholesterolemia is an important risk factor for coronary heart disease in Japan, as it is in Western countries. Importantly, the Westernization of lifestyle in Japan, particularly with respect to diet, has resulted in an overall increase in serum total cholesterol in the Japanese population. For example, the percentage of patients in Japan with total cholesterol levels over 220 mg/dl has risen from 17% in 1980 to 31% in 1990 (13) . Clearly, cholesterol reduction is an important concern not just for Western patients, but for Japanese patients as well.
In this paper, we present results from a placebo-controlled dose-ranging study of rosuvastatin 1 to 40 mg in Japanese patients with hypercholesterolemia.
Patients and Methods
This phase II study (4522IL/0055) was conducted between February 2000 and April 2001. The study was performed in accordance with Good Clinical Practice of Studies on Drugs and the Declaration of Helsinki and approval by the Institutional Review Board (IRB) of the institutions. Men aged 18-70 years and postmenopausal women aged 50-70 years with fasting LDL-C (Friedewald equation) > 160 and < 240 mg/dl and triglyceride (TG) < 300 mg/dl were enrolled in a 6-week dietary lead-in period at 23 study centers in Japan after providing written informed consent to participation. Exclusion criteria included use of a lipid-lowering drug within 4 weeks of enrollment, active arterial disease, body mass index > 30 kg/m 2 , active liver disease or dysfunction defined by elevations in liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma glutamyl transpeptidase, or alkaline phosphatase) or bilirubin > 1.5 times the upper limit of normal (ULN), serum creatinine > 2.0 mg/dl (180 µmol/l) and serum creatine kinase (CK) > 3 × ULN. To be eligible for randomized treatment, patients had to have fasting LDL-C > 160 and < 220 mg/dl and TG < 300 mg/dl at the final two visits during the lead-in phase (LDL-C measurements within 15% of each other).
Eligible patients were randomized in double-blind fashion to placebo or rosuvastatin 1, 2.5, 5, 10, 20, or 40 mg orally once daily for 6 weeks, with study medication taken not less than 3 hours after the evening meal, followed by a 4-week observational follow-up period.
The primary study objective was to assess the doseresponse relationship between rosuvastatin dose and percentage reduction in LDL-C from baseline with respect to placebo. Secondary objectives were to assess changes from baseline in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), TG, apolipoprotein (apo) B, apo A-I, and apo A-II and to assess safety of study treatment. Fasting lipids were measured at weeks -2, -1, 0, 1, 2, 4, and 6 (or at study withdrawal); baseline levels were the average of weeks -2, -1, and 0 values. All lipid analyses were performed by SRL Teijinbio Hachioji Laboratory in Tokyo. Blood samples (20 ml) were centrifuged at 1,500 G for 10 minutes at approximately 4˚C within 1 hour of sampling, with a 4.5-ml aliquot of serum being used for lipid analysis. LDL-C was measured by the Friedewald equation and the enzymatic method; HDL-C by the selective inhibitory method; total cholesterol and triglyceride by the enzymatic method; apo B, apo A-I, and apo A-II by immunoprecipitation.
The relationship between the log-transformed dose of rosuvastatin and percentage change from baseline in LDL-C and other lipid fractions was analyzed by logistic regression. In addition, changes from baseline in LDL-C and other lipid fractions were assessed using an analysis of variance (ANOVA). If percentage change was monotonic across dose levels, Williams' test was used for pairwise comparison of each dose with placebo. If percentage change was not monotonic, Dunnett's test was used for pairwise comparisons with placebo. Analyses of changes in lipid measures used a 0.05 two-sided significance level. All efficacy analyses are performed with the "full analysis set" of patients, comprising all patients who received study medication and had postdosing data available. Changes in lipid fractions from baseline at 6 weeks are reported as least-squares mean percentage changes from ANOVA with observed data in the full analysis set population.
The study sample size was based on the requirement of 12 patients per randomized treatment group to provide 90% power to demonstrate a 25% difference from placebo in LDL-C reduction (assuming a standard deviation of 15%) using a two-group t-test with a 0.05 twosided significance level and to adjust for multiple comparisons of treatment groups versus placebo. This sample size also permitted an estimate of the dose-response curve for percentage reduction in LDL-C having a confidence band width of < 10% for most of the dose range. The sample size reflected an expected 72-74% withdrawal rate during the dietary lead-in period.
Safety was assessed by physical examination, evaluation of vital signs, and various laboratory parameters. The safety assessment period included the 6-week randomized treatment phase and the 4-week follow-up period. Clinical laboratory assessments included biochemistry (including AST, ALT, gamma glutamyl transpeptidase, alkaline phosphatase, total bilirubin, total protein, CK, creatinine), hematology, and urinalysis. Adverse events were categorized according to an inventory based on the Coding Symbol and Thesau-rus for Adverse Reaction Terminology (COSTART). All data were summarized by treatment group.
Results
Of 369 patients entering the dietary lead-in phase, 113 patients were randomized to study treatment. One patient randomized to rosuvastatin 40 mg did not receive study medication and was excluded from efficacy and safety analyses. Demographic and baseline characteristics were similar among treatment groups (Table 1 ). In total, 59 patients (52.7%) were male, and the mean patient age was 55.3 years. Mean baseline LDL-C levels ranged from 181.0 to 190.0 mg/dl across the treatment groups. A total of nine patients withdrew from the study. One patient each in the rosuvastatin 2.5, 5, and 10 mg groups and two patients in the rosuvastatin 20 mg group withdrew because of adverse events; one patient in the rosuvastatin 1 mg group withdrew informed consent, one patient in the placebo group was withdrawn due to protocol noncompliance, and one patient each in the rosuvastatin 5 and 40 mg groups withdrew for other reasons. Six-week data for some parameters were available for one of these patients, who did not withdraw until the final visit. Data were missing for another three patients in the study at week 6.
Efficacy
Changes in lipid measures at 6 weeks with rosuvastatin and placebo and p values for slope of the regression line on linear regression analysis are shown in Table 2 . A linear dose response was observed for percentage reduction in LDL-C (p < 0.0001 for slope of regression line; slope -7.39) (Fig. 1) ; the relationship between the percentage change (y) and the log-transformed rosuvastatin dose (x) was expressed by the equation y = 36.84 -7.39x, with this relationship indicating that each doubling of rosuvastatin dose reduced LDL-C by an additional 5.12%.
Regression analysis showed a linear dose response for percentage reduction in TC and apo B, but not for changes in TG, apo A-I, or apo A-II. Mean reductions in LDL-C from baseline (least-squares mean percentage changes from ANOVA) ranged from 35.8 to 66.0% and were significant compared with placebo at every dose level. Reductions in TC ranged from 25.5 to 45.1% and were also significant at every dose level. Reductions in TG were 16.0 to 26.2% with a significant difference compared with placebo at the rosuvastatin 1 mg dose. Increases in HDL-C ranged from 7.5 to 12.8%, with significant differences compared with placebo observed at the 1-mg, 10-mg, and 20-mg doses. Decreases in apo B ranged from 31.9 to 57.8%, with reductions at all doses being significant compared with placebo. Increases in apo A-I ranged from 5.5 to 10.0% (significant at 10 and 20 mg), and increases in apo A-II ranged from 0.4 to 8.1% (significant at 10 and 20 mg). Substantial reductions in LDL-C:HDL-C, TC:HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios were observed at all doses (no statistical analysis performed). Fig. 1 . Relationship between the log dose of rosuvastatin (RSV) and percentage change from baseline in LDL-C (F-equation) at Week + 6. A linear dose response was observed for percentage reduction in LDL cholesterol (p < 0.0001 for slope of regression line; slope -7.39); each doubling of RSV dose reduces LDL-C by an additional 5.12%. Baseline values are mean (SD). Change is least-squares mean percentage change (SE) from baseline from ANOVA at week 6 using observed data in indicated number of patients. Week 6 values for lipid ratios are mean (SD) using observed data in indicated number of patients; no statistical analyses were performed for changes in lipid ratios. Apo = apolipoprotein; HDL-C = HDL cholesterol; LDL-C = LDL cholesterol; NA = not applicable; TC = total cholesterol; TG = triglyceride * Nine patients withdrew from the study. Lipid data is missing for three patients because measurements were taken outside specified time window of 6 weeks. ** For all variables except LDL-C and LDL-C:HDL-C ratio, for which n = 11. *** Linear regression analysis of relationship between log-transformed dose of rosuvastatin and percent change from baseline. 
Safety
Treatment-emergent adverse events (events that occurred or worsened during the 6-week randomized treatment administration period, or during the 4-week followup period) occurred in nine (60%) of 15 placebo recipients and 59 (61%) of 97 rosuvastatin recipients overall. Various categories of treatment-emergent adverse events in the rosuvastatin and placebo groups are shown in Table  3 . Three rosuvastatin patients (one each receiving 2.5, 10, and 20 mg) were described as withdrawn from the study because of treatment-emergent adverse events. Of these, one event (2.5 mg) was a pre-existing condition (clinically significant ophthalmic abnormalities) which should have excluded the patient, who was therefore withdrawn when this was recognized. The 10 mg case was an asthma attack in a known asthmatic, precipitated by acute bronchitis and considered unrelated to study treatment. The third event was gastrointestinal hemorrhage that occurred during the post-treatment follow-up period at 21 days after the last dose of rosuvastatin 20 mg; the investigator felt that there was no evidence to rule out the involvement of rosuvastatin in this case and that causality could not therefore be excluded. This case and the case of asthma that led to withdrawal were the only two treatment-emergent adverse events that met the criteria for serious adverse events. There were no deaths in the study. Treatment-related adverse eventsi.e., those considered by an investigator to be related to randomized treatment -occurred in three (20.0%) of 15 placebo patients and 27 (28%) of 97 rosuvastatin patients. The most frequently occurring treatment-related adverse events (coded by COSTART) were altered hormone level in the placebo patients (one female patient with low thyroid-stimulating hormone, one male patient with high thyroid-stimulating hormone, 13.3%), and abdominal pain (four patients, 4.1%) and increased CK (four patients, 4.1%) in the rosuvastatin patients.
Only one of the serious adverse events, as well as one of the adverse events leading to withdrawal, was considered treatment related (the same case of gastrointestinal hemorrhage). All treatment-emergent adverse events were mild or moderate in severity, except for the gastrointestinal hemorrhage and the asthma events described above, as well as an event of anemia reported in conjunction with the gastrointestinal hemorrhage. No patients exhibited clinically relevant increases in ALT or AST, defined as values ≥ 3 × ULN. One patient receiving rosuvastatin 5 mg had a CK value ≥ 3 × ULN. This patient engaged in periodic physical exercise (karate) and had exhibited an equivalent value prior to treatment; no muscle symptoms were associated with this increase, and the abnormality was not considered related to study treatment. No patients exhibited CK increases ≥ 5 × ULN.
Discussion
This study showed that rosuvastatin significantly reduces LDL-C in Japanese hypercholesterolemic patients and that its LDL-C -lowering effect is dose dependent over the range of 1 to 40 mg. Linear regression analysis indicates that each doubling of the rosuvastatin dose is associated with a 5.12% additional decrease in LDL-C. Linear dose response and significant reductions compared with placebo at all doses were also observed with rosuvastatin treatment for TC and apo B. Reductions in TG and increases in HDL-C and apo A-I were observed at all dose levels, with no dose-response effect being observed and differences compared with placebo being significant only at some doses.
These results are consistent with those previously reported for rosuvastatin treatment in hypercholesterolemic patients. In a study of 72 Japanese patients (TC > 220 In a randomized, placebo-controlled dose-ranging program of 142 European patients similar in design to the current study and having identical lipid entry criteria (7), rosuvastatin produced significant and dose-dependent decreases in LDL-C of 36-63% across a 1-to 40-mg dose range, with each doubling of dose producing an additional 5.2% decrease in LDL-C. Reductions in TC (25-46%) and apo B (29-55%) were also dose related and significant compared with placebo at all dose levels. Decreases in TG (10-35%) and increases in HDL-C (9-14%) were observed at all doses and were not dose related.
The effectiveness of rosuvastatin in reducing LDL-C and TC compares well with that observed with other statins in Japanese hypercholesterolemic patients (14) (15) (16) . Atorvastatin is considered the most effective of currently available statins in lowering LDL cholesterol (16, 17) . In a placebo-controlled randomized trial in 121 Japanese patients with TC ≥ 220 mg/dl and TG < 400 mg/dl (18), atorvastatin 5, 10, and 20 mg reduced LDL-C by 36-50% and TC by 27-38% in a dose-related manner at 8 weeks. Atorvastatin treatment reduced TG by 17-24%, increased HDL cholesterol by 7-15% and apo A-I by 4-6%, and changed apo A-II by -4% to + 1%, all in a non-doserelated manner. Rosuvastatin treatment was well tolerated. Only one patient discontinued the study because of an adverse event for which a relationship to study treatment could not be excluded, and this event was observed after completion of rosuvastatin 20 mg treatment. There was no clear dose-related trend in the incidence of treatmentemergent adverse events, although the incidence of those considered to be treatment-related appeared to be higher in the higher-dose rosuvastatin groups. All treatmentemergent adverse events were mild to moderate in severity except for the gastrointestinal hemorrhage observed in the rosuvastatin patient during follow-up, anemia reported in conjunction with this event, and the case of asthma that led to withdrawal. No patients had clinically significant elevations in serum transaminases or other findings suggesting clinically relevant effects on liver function. There were no cases of myopathy (defined as CK > 10 × ULN with muscle symptoms); one patient exhibited a CK value ≥ 3 × ULN in apparent association with periodic physical exercise, and no patients exhibited CK ≥ 5 × ULN.
In conclusion, rosuvastatin is an effective novel statin that produces dose-related reductions in LDL-C at doses of 1 to 40 mg in Japanese hypercholesterolemic patients. Rosuvastatin treatment was well tolerated and did not appear to produce any unexpected or clearly dose-related adverse effects.
